Treatment of Depression in the Elderly
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00130455|
Recruitment Status : Terminated
First Posted : August 15, 2005
Last Update Posted : February 6, 2007
The study is designed to establish the efficacy and tolerability of escitalopram in the treatment of depressive episodes of mild to moderate severity in the elderly.
The study is designed as a mainly naturalistic study including all patients of 65 years of age or above that judged by the clinician would benefit from treatment by an antidepressant medication. The study is designed as a double-blind, randomised placebo controlled study with two groups of active treatment (escitalopram in two doses, 5 or 10 mg daily) in a twelve week period.
|Condition or disease||Intervention/treatment||Phase|
|Depression||Drug: escitalopram||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||189 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A 12 Week Multi-Centre, Randomized, Double-Blind, Placebo Controlled Evaluation of the Most Efficacious and Tolerable Dose of Escitalopram in the Treatment of Elderly Patients|
|Study Start Date :||April 2006|
|Study Completion Date :||January 2008|
- Remission during the study is defined as a Hamilton 6-item depression subscale (HAM-D6) score less than or equal to 4
- Response will be defined as a drop in HAM-D6 score of 50% or more
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00130455
|Hilleroed, Denmark, DK-3400|
|Principal Investigator:||Alex Koerner, MD||Psychiatric hospital, Hilleroed, Denmark|